These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2655 related items for PubMed ID: 7901150

  • 1. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V, Schild HJ, Gückel B, von Hoegen P.
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [Abstract] [Full Text] [Related]

  • 2. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
    Kern DE, Klarnet JP, Jensen MC, Greenberg PD.
    J Immunol; 1986 Jun 01; 136(11):4303-10. PubMed ID: 2422280
    [Abstract] [Full Text] [Related]

  • 3. The activation of L3T4+ helper T cells assisting the generation of anti-tumor Lyt-2+ cytotoxic T lymphocytes: requirement of Ia-positive antigen-presenting cells for processing and presentation of tumor antigens.
    Kosugi A, Yoshioka T, Suda T, Sano H, Takahama Y, Fujiwara H, Hamaoka T.
    J Leukoc Biol; 1987 Dec 01; 42(6):632-41. PubMed ID: 2960766
    [Abstract] [Full Text] [Related]

  • 4. Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.
    Herrmann T, Maryanski JL, Romero P, Fleischer B, MacDonald HR.
    J Immunol; 1990 Feb 15; 144(4):1181-6. PubMed ID: 1968075
    [Abstract] [Full Text] [Related]

  • 5. Cytotoxic T lymphocyte precursor cells specific for the major histocompatibility complex class I-like antigen, Qa-2, require CD4+ T cells to become primed in vivo and to differentiate into effector cells in vitro.
    Muraoka S.
    Eur J Immunol; 1991 Sep 15; 21(9):2095-103. PubMed ID: 1679712
    [Abstract] [Full Text] [Related]

  • 6. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
    McMenamin C, Holt PG.
    J Exp Med; 1993 Sep 01; 178(3):889-99. PubMed ID: 8102390
    [Abstract] [Full Text] [Related]

  • 7. Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes.
    Wu JY, Gardner BH, Kushner NN, Pozzi LA, Kensil CR, Cloutier PA, Coughlin RT, Newman MJ.
    Cell Immunol; 1994 Apr 01; 154(1):393-406. PubMed ID: 7907530
    [Abstract] [Full Text] [Related]

  • 8. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
    Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G.
    Scand J Immunol; 1995 Apr 01; 41(4):357-64. PubMed ID: 7899823
    [Abstract] [Full Text] [Related]

  • 9. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y, Mayumi H, Eto M, Nomoto K.
    J Immunol; 1990 Mar 15; 144(6):2425-35. PubMed ID: 1968930
    [Abstract] [Full Text] [Related]

  • 10. CD4-CD8- T cell receptor alpha beta T cells: generation of an in vitro major histocompatibility complex class I specific cytotoxic T lymphocyte response and allogeneic tumor rejection.
    Mieno M, Suto R, Obata Y, Udono H, Takahashi T, Shiku H, Nakayama E.
    J Exp Med; 1991 Jul 01; 174(1):193-201. PubMed ID: 1905338
    [Abstract] [Full Text] [Related]

  • 11. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG.
    Prostate; 2002 Nov 01; 53(3):183-91. PubMed ID: 12386918
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen.
    Rock KL, Rothstein L, Fleischacker C, Gamble S.
    J Immunol; 1992 May 15; 148(10):3028-33. PubMed ID: 1578128
    [Abstract] [Full Text] [Related]

  • 13. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S, Komita H, Sagawa Y, Ohno T, Toda G.
    Immunology; 2005 Aug 15; 115(4):451-61. PubMed ID: 16011514
    [Abstract] [Full Text] [Related]

  • 14. Analysis of T-T lymphocytes and T-accessory cell interactions using cloned T cells: MHC I restricted cloned T cells activate MHC II restricted T helper cells.
    Brückner T, Di Pauli R.
    Cell Immunol; 1986 Apr 15; 99(1):182-95. PubMed ID: 2875800
    [Abstract] [Full Text] [Related]

  • 15. Interplay between the TCR/CD3 complex and CD4 or CD8 in the activation of cytotoxic T lymphocytes.
    de Vries JE, Yssel H, Spits H.
    Immunol Rev; 1989 Jun 15; 109():119-41. PubMed ID: 2527803
    [Abstract] [Full Text] [Related]

  • 16. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A, Shiku H, Nakayama E.
    J Immunol; 1993 Jun 01; 150(11):4900-10. PubMed ID: 8496592
    [Abstract] [Full Text] [Related]

  • 17. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo.
    Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss H.
    J Exp Med; 1994 Mar 01; 179(3):865-72. PubMed ID: 8113680
    [Abstract] [Full Text] [Related]

  • 18. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL, Lake RA, Robinson BW, Scott B.
    Cancer Res; 1999 Mar 01; 59(5):1071-9. PubMed ID: 10070965
    [Abstract] [Full Text] [Related]

  • 19. The influence of allo-class II MHC-specific Th2 cells on the generation of CD4 and CD8 cytotoxic T cells to associated class I and class II MHC alloantigen.
    Wood PJ, Cossens IA.
    Clin Exp Immunol; 1995 May 01; 100(2):359-65. PubMed ID: 7743677
    [Abstract] [Full Text] [Related]

  • 20. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
    Mangino G, Grazia Capri M, Barnaba V, Alberti S.
    Int J Cancer; 2002 Oct 01; 101(4):353-9. PubMed ID: 12209960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 133.